Average deal value has climbed to $527 million per transaction, with large-cap pharma companies pursuing late-stage assets to offset looming revenue losses from exclusivity expiries.
Newsflash:
The allogeneic GABAergic interneuron cell therapy reported durable seizure suppression beyond 13 months in drug-resistant mesial temporal …
Average deal value has climbed to $527 million per transaction, with large-cap pharma companies pursuing late-stage assets to offset looming revenue losses from exclusivity expiries.
The allogeneic GABAergic interneuron cell therapy reported durable seizure suppression beyond 13 months in drug-resistant mesial temporal …
Average deal value has climbed to $527 million per transaction, with large-cap pharma companies pursuing late-stage assets to offset looming revenue losses from exclusivity expiries.
The allogeneic GABAergic interneuron cell therapy reported durable seizure suppression beyond 13 months in drug-resistant mesial temporal …
LEADERS
INVESTMENTS
INNOVATION
PARTNERSHIPS
In-Depth Analysis
In-Depth Analysis
Explore our longform features and deep dives into biotech breakthroughs and innovation.
Expert Opinions
Expert Opinions
Read opinions and commentary from leading scientists, investors, and pharma leaders.
Funding & IPOs
Funding & IPOs
Track the latest funding rounds, IPO announcements, and investment trends in biotech/pharma.
Clinical Results & Milestones
Clinical Results & Milestones
Stay informed on pivotal trial results, FDA approvals, and key clinical milestones.
1
2
3
4
5
6
7
8
9
10
1
2
3
4
5
6
7
8
9
10
The Reporter Newsletter
Expert picks and exclusive deals, in your inbox.
The TGA has granted conditional approval to Iovance Biotherapeutics’ lifileucel, an autologous tumour-infiltrating lymphocyte therapy, bringing a new treatment option to a country where melanoma claims more than 1,700 lives per year.
The TGA has granted conditional approval to Iovance Biotherapeutics’ lifileucel, an autologous tumour-infiltrating lymphocyte therapy, bringing a new treatment option to a country where melanoma claims more than 1,700 lives per year.
Watch Now
Depot blast in Bangladesh kills nearly 50 people - BBC News
Russia accused of stealing about 600,000 tonnes of Ukraine's grain - BBC News
Devastation of Australia's climate change crisis captured on camera - BBC News
Boris Johnson survives leadership vote but 41% of his MPs have “no confidence” - BBC News
The FDA approval of Xocova marks a new front in the antiviral arsenal, shifting from treatment to prevention for close …
Major investment strengthens pharmaceutical supply chain resilience and advances green manufacturing practices in North America.
Listen Now
Triple-drug combination extending life for women with aggressive HR+/HER2− breast cancer
Led by Founders Fund and Thrive Capital, the round reflects sustained institutional conviction in cellular rejuvenation biology as a tractable approach to slowing or reversing hallmarks of biological ageing.
Average deal value has climbed to $527 million per transaction, with large-cap pharma companies pursuing late-stage assets to offset looming revenue losses from exclusivity expiries.
The global Alzheimer’s disease drug development pipeline has reached an unprecedented scale in 2026, with 192 active clinical trials assessing 158 novel therapeutic agents, according to data released by the Alzheimer’s Association. The figures mark a substantial expansion from the 182 trials and 138 drugs tracked in the 2025 pipeline and reflect a broadening of …
Ready To Explore Industry News?
All articles are free -no payment or registration required.
Already a subscriber?